Hepatic ischemia-reperfusion and mitochondrial quality control: potential therapeutic targets
International Immunopharmacology · 2025-10 · 163 · 115267
DOI: 10.1016/j.intimp.2025.115267 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025-10. Verfasst von Junqi Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing University of Traditional Chinese Medicine, Beijing 100029, China. Hauptthemen laut MEDLINE: Reperfusion Injury, Liver, Mitochondria, Liver Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 204 Literaturangaben. Gefördert von: China Academy of Chinese Medical Sciences.
Abstract (Originalsprache)
BACKGROUND: Hepatic ischemia-reperfusion injury (HIRI) represents a significant challenge in liver surgical procedures. This complex pathology arises from the interplay of inflammation, oxidative damage, and regulated cell death cascades. Compromised mitochondrial function critically contributes to HIRI progression. Consequently, maintaining cellular equilibrium necessitates effective mitochondrial quality control (MQC), a fundamental axis encompassing mitochondrial autophagy, dynamic remodeling, biogenesis, and the mitochondrial unfolded protein response (UPRmt). KEY MECHANISMS: Mitophagy: Selectively removes damaged mitochondria via PINK1/Parkin (ubiquitin-dependent) and BNIP3/FUNDC1 (ubiquitin-independent) pathways. Impaired mitophagy during ischemia-reperfusion exacerbates mitochondrial damage, while enhancing it (e.g., via PEG35, Sirtuin activators) mitigates injury. Mitochondrial Dynamics: The stability of the mitochondrial network is critically dependent on the equilibrium between fusion, regulated by Mfn1, Mfn2, and Opa1, and fission, mediated by Drp1. HIRI disrupts this equilibrium, promoting fragmentation and apoptosis. Pharmacological agents (e.g., DEX, exogenous irisin) restore dynamics by modulating Drp1 and fusion proteins. Biogenesis: The PGC-1α/NRF-1/TFAM axis drives mitochondrial renewal. HIRI suppresses biogenesis, but interventions (e.g., ADSC-exo, genipin) enhance ATP production and mitochondrial DNA replication. THERAPEUTIC INTERVENTIONS: Pharmacological strategies targeting MQC components demonstrate efficacy: Mitophagy: PEG35 enhances ALDH2-mediated LC3 conversion; quercetin regulates SIRT1/TMBIM6. Dynamics: COX-2 inhibitors and SIRT3 deacetylate Opa1 to promote fusion. Biogenesis: Irisin and NRF2 activators upregulate PGC-1α/TFAM, restoring mitochondrial mass. CONCLUSION: MQC mechanisms are pivotal in HIRI pathogenesis. Targeting mitophagy, dynamics, and biogenesis offers promising therapeutic avenues to attenuate inflammation, oxidative stress, and cell death. Translational research on MQC modulators (e.g., PEG35, Sirt1 activators) may yield novel treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing University of Traditional Chinese Medicine, Beijing 100029, China.
- Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China.
- Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong (CUHK), Hong Kong SAR, China. Electronic address: sangbingong@cuhk.edu.hk.
- Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Cardiology, Senior Department of Cardiology, Pla general hospital, Beijing, China. Electronic address: zhouhao301@outlook.com.
- Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China. Electronic address: xingchang_tcm@outlook.com.
Förderung
- China Academy of Chinese Medical Sciences
Zitieren
APA
Wang, J., Fu, W., Lu, N., Guo, Z., Bing, O. S., Shi, H., Zhou, H., Chang, X., & Meng, M. (2025). Hepatic ischemia-reperfusion and mitochondrial quality control: potential therapeutic targets. International Immunopharmacology, 163, 115267. https://doi.org/10.1016/j.intimp.2025.115267
Vancouver
Wang J, Fu W, Lu N, Guo Z, Bing OS, Shi H, et al. Hepatic ischemia-reperfusion and mitochondrial quality control: potential therapeutic targets. International Immunopharmacology. 2025;163:115267. doi:10.1016/j.intimp.2025.115267
BibTeX
@article{Wang2025,
author = {Wang, Junqi and Fu, Wenkai and Lu, Nan and Guo, Zhijiang and Bing, Ong Sang and Shi, Hongshuo and Zhou, Hao and Chang, Xing and Meng, Miao},
title = {Hepatic ischemia-reperfusion and mitochondrial quality control: potential therapeutic targets},
journal = {International Immunopharmacology},
year = {2025},
volume = {163},
pages = {115267},
doi = {10.1016/j.intimp.2025.115267}
}
EUVIMED